Advertisement Aerocrine receives clearance to market asthma device - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Aerocrine receives clearance to market asthma device

Aerocrine has reported that Niox Mino, a hand-held point-of-care device for the measurement of airway inflammation, has received 510(k) clearance from the FDA.

Niox Mino provides accurate, reproducible and immediate measurement of fractional exhaled nitric oxide, a validated method for assessing asthma-related airway inflammation. Niox Mino is said to be the first hand-held device to measure airway inflammation — an underlying cause of inflammatory airway diseases — helping physicians improve patient outcomes and reduce healthcare expenditures.

Peter Boggs, clinical professor of pediatrics and medicine, LSU School of Medicine, Shreveport, said: “Niox Mino answers the need for a user friendly, non-invasive, accurate, and cost effective tool that enables any physician to monitor the underlying process of asthma-airway inflammation.”